Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis
Jolijn R van Leeuwen,1,* Tamara Popov,2,* Achim Obergfell,2 Ton J Rabelink,1 YK Onno Teng1 1Center of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases (LuVaCs), Department of Internal Medicine - Nephrology Section, Leiden University Medical Center, Leiden,...
Main Authors: | van Leeuwen JR, Popov T, Obergfell A, Rabelink TJ, Teng YKO |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-01-01
|
Series: | Biologics: Targets & Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/preliminary-assessment-of-safety-and-tolerability-of-avacopan-during-t-peer-reviewed-fulltext-article-BTT |
Similar Items
-
Journal Club Review of “Avacopan for the Treatment of ANCA‐Associated Vasculitis”
by: William Daniel Soulsby
Published: (2022-07-01) -
Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
by: John L Niles, et al.
Published: (2023-07-01) -
Immunopathogenesis of ANCA-Associated Vasculitis
by: Andreas Kronbichler, et al.
Published: (2020-10-01) -
ANCA-Associated Vasculitis: An Update
by: Salem Almaani, et al.
Published: (2021-04-01) -
Updates in ANCA-associated vasculitis
by: Carolyn Ross, et al.
Published: (2022-07-01)